Description: In recent days, Revvity, Inc. updated its outlook for the fourth quarter and full year 2025, guiding to approximately US$772,000,000 in Q4 revenue and about US$2.86 billion for the year, while indicating adjusted earnings per share should exceed its prior guidance range. A separate announcement revealed that Revvity and Eli Lilly are jointly expanding access to Lilly’s TuneLab AI models through Revvity’s Signals platform, underscoring Revvity’s push to embed advanced AI and federated...

Description: ↘️JPMorgan Chase (JPM): The Wall Street bastion posted a 7% drop in quarterly profit, while revenue missed forecasts. Investment-banking fees fell. JPMorgan took an extra $2.2 billion charge for potential futures losses related to buying Apple (AAPL)'s credit-card program.

Description: US equity futures turned slightly higher ahead of Tuesday's opening bell as traders digested the Dec

Description: Wall Street is split on the stock, and the shares are close to the average price target. Something's got to give.

Description: WALTHAM, Mass., January 12, 2026--Revvity, Inc. (NYSE: RVTY), today announced that it will release its fourth quarter and full year 2025 financial results prior to market open on Monday, February 2, 2026. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.

Description: Revvity teams up with Eli Lilly to bring TuneLab AI models to Signals Xynthetica, aiming to unlock secure, federated drug discovery at scale.

Description: WALTHAM, Mass., January 09, 2026--Revvity, Inc. (NYSE: RVTY) today announced a collaboration with Eli Lilly and Company (Lilly) that expands access to Lilly’s high-quality predictive models by making Lilly TuneLab available through the Revvity Signals platform. The collaboration builds on Revvity’s recently introduced Signals XyntheticaTM offering, creating a scalable, federated framework designed to accelerate AI-enabled drug discovery.

Description: Key Insights Revvity's estimated fair value is US$128 based on 2 Stage Free Cash Flow to Equity Revvity's US$105 share...

Description: Revvity is set to announce its fourth-quarter results soon, and analysts expect a single-digit rise in its adjusted earnings per share.

Description: Diamond Hill Capital, an investment management company, released its “Mid Cap Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Markets continued their rally in the third quarter, with US stocks gaining over 8% as measured by the Russell 3000 Index. Small-cap stocks experienced the strongest quarterly performance, rising by […]

Description: RVTY unveils Signals Xynthetica, an AI-augmented design platform that links predictive models with real lab data to speed discovery.

Description: WALTHAM, Mass., December 18, 2025--Revvity, Inc. (NYSE: RVTY) will present at the 44th annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 9:45 a.m. PT.

Description: Revvity (NYSE:RVTY) has had a great run on the share market with its stock up by a significant 10% over the last three...

Description: WALTHAM, Mass., December 16, 2025--Revvity, Inc. (NYSE: RVTY) today announced the introduction of its forthcoming Signals Xynthetica™ Models-as-a Service (MaaS) AI offering within the Revvity Signals platform. The Signals Xynthetica offering will enable AI-augmented molecular and materials design, and brings together advanced in‑silico generation, predictive modeling, and experimental validation within a single, governed environment that allows scientific teams to iteratively design, test, and r

Description: Revvity has underperformed the Health Care industry over the past year, but analysts are moderately optimistic about the stock’s prospects.

Description: Investing.com -- Goldman Sachs has launched coverage of the Life Sciences Tools sector with a selective stance, arguing that the group should ultimately “return to their historic market growth rate of ~5%,” but only as certain end markets recover faster than others.

Description: VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the inclusion of its Nu.Q® NETs H3.1 assay in "DETECSEPS", a real-world evaluation of early detection of sepsis. DETECSEPS Consortium was awarded winner of the "Challenge Prevention" call for proposals launched by the French Health Innovation Agency and operated by the Banque Publique d'Investissement, as part of the France 2030 plan, during the official ceremony held yesterday, December

Description: Revvity (RVTY) shares have drawn investor attention after the company released its latest financial results, which highlight annual growth in both revenue and net income. The market is reacting to these numbers, particularly in the context of recent sector trends. See our latest analysis for Revvity. Revvity's stock rebounded strongly this past week, with a seven-day share price return of over 13 percent. This helped to reverse some of the pressure seen earlier this year. Still, with a...

Description: Revvity (RVTY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to

Description: Revvity has notably underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

Description: Investors were disappointed with the weak earnings posted by Revvity, Inc. ( NYSE:RVTY ). Despite the soft profit...

Description: Revvity (NYSE:RVTY) just released its third-quarter earnings, with sales ticking higher while net income came in below last year. The company also updated its full-year outlook to reflect currency changes and announced a major share buyback program. See our latest analysis for Revvity. Revvity’s string of updates, including its $1 billion share buyback and solid sales growth, have helped the stock regain some momentum after a tough year. While the 90-day share price return is up 3.2%, the...

Description: WALTHAM, Mass., November 10, 2025--Revvity, Inc., today announced the launch of new highly-characterized somatic cancer reference standards developed in collaboration with the Medical Device Innovation Consortium (MDIC) and the National Institute of Standards and Technology (NIST) as part of the Somatic Reference Samples (SRS) Initiative.

Description: WALTHAM, Mass., November 10, 2025--Revvity, Inc. (NYSE: RVTY), today announced it has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical and material sciences end markets. This acquisition expands the breadth and depth of Revvity Signals’ solutions for bridging the gap between analytical data and actionable insights, further strengthening its ability to acc

Description: Revvity’s third quarter results were met with a significant negative reaction from the market, as investors focused on sluggish organic revenue growth and margin compression despite headline results aligning with Wall Street expectations. Management pointed to a strong performance in its Signals software and reproductive health businesses, with CEO Prahlad R. Singh highlighting that “our signals software business continued to perform extremely well, growing 20% organically,” and that “newborn sc

Description: Revvity (RVTY) delivered a strong performance in its latest earnings, with net profit margins expanding to 10% from last year’s 7.3% and annual earnings growing 41.3% year over year. This result stands out compared to its five-year average decline of 32.5% per year. Looking ahead, earnings are expected to grow at 27.8% annually while the share price of $97.16 trades below the estimated fair value of $135.5. This suggests constructive sentiment around both profit quality and valuation relative...

Description: WALTHAM, Mass., October 28, 2025--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences:

Description: Companies In The News Are: ARLP, DQ, KDP, RVTY.

Description: Life sciences company Revvity (NYSE:RVTY) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 2.2% year on year to $698.9 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $2.86 billion at the midpoint. Its non-GAAP profit of $1.18 per share was 3.6% above analysts’ consensus estimates.

Description: Revvity Inc (RVTY) reports robust Q3 performance with notable gains in software growth and strategic financial maneuvers, despite challenges in China Diagnostics.

Description: Shares of life sciences company Revvity (NYSE:RVTY) fell 2.4% in the afternoon session after it reported third-quarter financial results that showed a drop in profits and margins, even as revenue grew.

Description: Revvity beats on Q3 earnings and raises 2025 EPS view, as balanced segment performance offsets margin pressure.

Description: Although the revenue and EPS for Revvity (RVTY) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Description: The benchmark US stock measures were tracking in the green before the opening bell Monday as Preside

Description: Revvity (RVTY) delivered earnings and revenue surprises of +3.51% and -0.15%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Life sciences company Revvity (NYSE:RVTY) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 2.2% year on year to $698.9 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $2.86 billion at the midpoint. Its non-GAAP profit of $1.18 per share was 3.6% above analysts’ consensus estimates.

Description: WALTHAM, Mass. AP) — Revvity, Inc. RVTY) on Monday reported third-quarter earnings of $46.7 million.

Description: WALTHAM, Mass., October 27, 2025--Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended September 28, 2025.

Description: Life sciences company Revvity (NYSE:RVTY) will be announcing earnings results this Monday before the bell. Here’s what you need to know.

Description: Thinking about what to do with Revvity stock? You are definitely not alone. Every investor wants to catch a stock on the upswing or before a major turnaround. Revvity has given folks plenty to talk about lately. After a challenging stretch, shares have come roaring back in the past month and climbed 17.6%, including a 5.9% gain just this past week. That's impressive by most standards, and it is a sharp contrast to the company's longer-term performance, which still shows the stock down 11.7%...

Description: WALTHAM, Mass., October 23, 2025--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on February 6, 2026 to all shareholders of record at the close of business on January 16, 2026.

Description: RVTY's third-quarter results are likely to reflect strong performance in the Life Sciences segment. However, the Diagnostic segment is set to face challenges in China.

Description: Get a deeper insight into the potential performance of Revvity (RVTY) for the quarter ended September 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Description: Labcorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.